Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial

被引:29
|
作者
Imamura, Hiroshi [2 ]
Kurokawa, Yukinori [1 ]
Tsujinaka, Toshimasa [3 ]
Inoue, Kentaro [4 ]
Kimura, Yutaka [5 ]
Iijima, Shohei [6 ]
Shimokawa, Toshio [7 ]
Furukawa, Hiroshi [2 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Suita, Osaka, Japan
[2] Sakai Municipal Hosp, Dept Surg, Osaka, Japan
[3] Osaka Natl Hosp, Dept Surg, Osaka, Japan
[4] Kansai Med Coll, Dept Surg, Osaka, Japan
[5] NTT W Hosp, Dept Surg, Osaka, Japan
[6] Minoh City Hosp, Dept Surg, Osaka, Japan
[7] Univ Yamanashi, Grad Sch Med & Engn, Yamanashi, Japan
来源
LANCET INFECTIOUS DISEASES | 2012年 / 12卷 / 05期
关键词
SURGICAL-SITE INFECTION; ANTIBIOTIC-PROPHYLAXIS; NODAL DISSECTION; RISK-FACTORS; PREVENTION; D2; LYMPHADENECTOMY;
D O I
10.1016/S1473-3099(11)70370-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Although evidence for the efficacy of postoperative antimicrobial prophylaxis is scarce, many patients routinely receive such treatment after major surgeries. We aimed to compare the incidence of surgical-site infections with intraoperative antimicrobial prophylaxis alone versus intraoperative plus postoperative administration. Methods We did a prospective, open-label, phase 3, randomised study at seven hospitals in Japan. Patients with gastric cancer that was potentially curable with a distal gastrectomy were randomly assigned (1:1) to receive either intraoperative antimicrobial prophylaxis alone (cefazolin 1 g before the surgical incision and every 3 h as intraoperative supplements) or extended antimicrobial prophylaxis (intraoperative administration plus cefazolin 1 g once after closure and twice daily for 2 postoperative days). Randomisation was stratified using Pocock and Simon's minimisation method for institution and American Society of Anesthesiologists scores, and Mersenne twister was used for random number generation. The primary endpoint was the incidence of surgical-site infections. We assessed non-inferiority of intraoperative therapy with a margin of 5%. Analysis was by intention-to-treat. During hospital stay, infection-control personnel assessed patients for infection, and the principal surgeons were required to check for surgical-site infections at outpatient clinics until 30 days after surgery. This study is registered with UMIN-CTR, UMIN000000631. Findings Between June 2,2005, and Dec 6,2007,355 patients were randomly assigned to receive either intraoperative antimicrobial prophylaxis alone (n=176) or extended antimicrobial prophylaxis (n=179). Eight patients (5%, 95% CI 2-9%) had surgical-site infections in the intraoperative group compared with 16 (9%, 5-14) in the extended group. The relative risk of surgical-site infections with intraoperative antimicrobial prophylaxis was 0.51 (0.22-1.16), which revealed statistically significant non-inferiority (p<0-0001). Interpretation Elimination of postoperative antimicrobial prophylaxis did not increase the incidence of surgical-site infections after a gastrectomy. Therefore, this treatment is not recommended after gastric cancer surgery. Funding Osaka Gastrointestinal Cancer Chemotherapy Study Group.
引用
收藏
页码:381 / 387
页数:7
相关论文
共 50 条
  • [42] Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial
    Stupica, Dasa
    Collinet-Adler, Stefan
    Blagus, Rok
    Gomiscek, Anja
    Kisek, Tjasa Cerar
    Ruzic-Sabljic, Eva
    Veluscek, Masa
    LANCET INFECTIOUS DISEASES, 2023, 23 (03): : 371 - 379
  • [43] Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial (vol 15, pg 767, 2014)
    Jeong, S-Y
    Park, J. W.
    Nam, B. H.
    LANCET ONCOLOGY, 2016, 17 (07): : E270 - E270
  • [44] Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial
    Paton, Nicholas I.
    Stoehr, Wolfgang
    Arenas-Pinto, Alejandro
    Fisher, Martin
    Williams, Ian
    Johnson, Margaret
    Orkin, Chloe
    Chen, Fabian
    Lee, Vincent
    Winston, Alan
    Gompels, Mark
    Fox, Julie
    Scott, Karen
    Dunn, David T.
    LANCET HIV, 2015, 2 (10): : E417 - E426
  • [45] Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial
    Kurokawa, Yukinori
    Doki, Yuichiro
    Mizusawa, Junki
    Terashima, Masanori
    Katai, Hitoshi
    Yoshikawa, Takaki
    Kimura, Yutaka
    Takiguchi, Shuji
    Nishida, Yasunori
    Fukushima, Norimasa
    Iwasaki, Yoshiaki
    Kaji, Masahide
    Hirao, Motohiro
    Katayama, Hiroshi
    Sasako, Mitsuru
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (07): : 460 - 468
  • [46] SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial
    de Wit, Leon
    Rademaker, Doortje
    Voormolen, Daphne N.
    Akerboom, Bettina M. C.
    Kiewiet-Kemper, Rosalie M.
    Soeters, Maarten R.
    Verwij-Didden, Marion A. L.
    Assouiki, Fahima
    Schippers, Daniela H.
    Vermeulen, Mechteld A. R.
    Kuppens, Simone M. I.
    Oosterwerff, Mirjam M.
    Zwart, Joost J.
    Diekman, Mattheus J. M.
    Vogelvang, Tatjana E.
    Gallas, P. Rob J.
    Galjaard, Sander
    Visser, Willy
    Horree, Nicole
    Klooker, Tamira K.
    Laan, Rosemarie
    Heijligenberg, Rik
    Huisjes, Anjoke J. M.
    van Bemmel, Thomas
    van Meir, Claudia A.
    van den Beld, Annewieke W.
    Hermes, Wietske
    Vidarsdottir, Solrun
    Veldhuis-Vlug, Anneke G.
    Dullemond, Remke C.
    Jansen, Henrique J.
    Sueters, Marieke
    de Koning, Eelco J. P.
    van Laar, Judith O. E. H.
    Wouters-van Poppel, Pleun
    Sanson-van Praag, Marina E.
    van den Akker, Eline S.
    Brouwer, Catherine B.
    Hermsen, Brenda B.
    Potter van Loon, Bert Jan
    van der Heijden, Olivier W. H.
    de Galan, Bastiaan E.
    van Leeuwen, Marsha
    Wijbenga, Johanna A. M.
    de Boer, Karin
    van Bon, Arianne C.
    van der Made, Flip W.
    Eskes, Silvia A.
    Zandstra, Mirjam
    van Houtum, William H.
    BMJ OPEN, 2019, 9 (08):
  • [47] Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial
    Hu, Chao-su
    Xue, Fen
    Ou, Dan
    Xie, Congying
    Lin, Shaojun
    Li, Jingao
    Chen, Xiaozhong
    Zhang, Fuzheng
    Ying, Hongmei
    Lu, Xueguan
    Shen, Chunying
    Xu, Tingting
    Ou, Xiaomin
    Zhou, Xin
    Du, Chengrun
    Li, Weiwei
    He, Xiayun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Breakdown of simple female genital fistula repair after 7 day versus 14 day postoperative bladder catheterisation: a randomised, controlled, open-label, non-inferiority trial
    Barone, Mark A.
    Widmer, Mariana
    Arrowsmith, Steven
    Ruminjo, Joseph
    Seuc, Armando
    Landry, Evelyn
    Barry, Thierno Hamidou
    Danladi, Dantani
    Djangnikpo, Lucien
    Gbawuru-Mansaray, Tagie
    Harou, Issoufa
    Lewis, Alyona
    Muleta, Mulu
    Nembunzu, Dolores
    Olupot, Robert
    Sunday-Adeoye, Ileogben
    Wakasiaka, Weston Khisa
    Landoulsi, Sihem
    Delamou, Alexandre
    Were, Lilian
    Frajzyngier, Vera
    Beattie, Karen
    Guelmezoglu, A. Metin
    LANCET, 2015, 386 (9988): : 56 - 62
  • [49] Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial (vol 6, pg 569, 2021)
    Park, J. W.
    Kang, S-B
    Hao, J.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : E7 - E7
  • [50] Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial
    Robert, Maud
    Espalieu, Philippe
    Pelascini, Elise
    Caiazzo, Robert
    Sterkers, Adrien
    Khamphommala, Lita
    Poghosyan, Tigran
    Chevallier, Jean-Marc
    Malherbe, Vincent
    Chouillard, Elie
    Reche, Fabian
    Torcivia, Adriana
    Maucort-Boulch, Delphine
    Bin-Dorel, Sylvie
    Langlois-Jacques, Carole
    Delaunay, Dominique
    Pattou, Francois
    Disse, Emmanuel
    LANCET, 2019, 393 (10178): : 1299 - 1309